Počet záznamů: 1
Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice
- 1.
SYSNO ASEP 0488092 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice Tvůrce(i) Mikyšková, Romana (UMG-J) RID
Indrová, Marie (UMG-J) RID
Štěpánek, Ivan (UMG-J) RID
Kanchev, Ivan (UMG-J) RID
Bieblová, Jana (UMG-J)
Vošahlíková, Š. (CZ)
Moserová, I. (CZ)
Truxová, I. (CZ)
Fučíková, J. (CZ)
Bartunkova, J. (CZ)
Spisek, R. (CZ)
Sedláček, Radislav (UMG-J) RID
Reiniš, Milan (UMG-J) RIDCelkový počet autorů 13 Číslo článku e1362528 Zdroj.dok. Oncoimmunology - ISSN 2162-402X
Roč. 6, č. 12 (2017)Poč.str. 11 s. Jazyk dok. eng - angličtina Země vyd. US - Spojené státy americké Klíč. slova dendritic cells ; docetaxel ; high hydrostatic pressure ; immunotherapy ; prostate cancer Vědní obor RIV EB - Genetika a molekulární biologie Obor OECD Immunology CEP LM2015040 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy ED1.1.00/02.0109 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy ED2.1.00/19.0395 GA MŠMT - Ministerstvo školství, mládeže a tělovýchovy GA15-24769S GA ČR - Grantová agentura ČR Institucionální podpora UMG-J - RVO:68378050 UT WOS 000419128300006 DOI 10.1080/2162402X.2017.1362528 Anotace Dendritic cell (DC)-based vaccines pulsed with high hydrostatic pressure (HHP)-inactivated tumor cells have recently been shown to be a promising tool for prostate cancer chemoimmunotherapy. In this study, DC-based vaccines, both pulsed and unpulsed, were as effective as docetaxel (DTX) in reducing prostate tumors in the orthotopic transgenic adenocarcinoma of the mouse prostate (TRAMP) model. However, we did not observe any additive or synergic effects of chemoimmunotherapy on the tumor growth, while only the combination of DTX and pulsed dendritic cells resulted in significantly lower proliferation detected by Ki67 staining in histological samples. The DC-based vaccine pulsed with HHP-treated tumor cells was also combined with another type of cytostatic, cyclophosphamide, with similar results. In another clinically relevant setting, minimal residual tumor disease after surgery, administration of DC-based vaccines after the surgery of poorly immunogenic transplanted TRAMP-C2, as well as in immunogenic TC-1 tumors, reduced the growth of tumor recurrences. To identify the effector cell populations after DC vaccine application, mice were twice immunized with both pulsed and unpulsed DC vaccine, and the cytotoxicity of the spleen cells populations was tested. The effector cell subpopulations were defined as CD4(+) and NK1.1(+), which suggests rather unspecific therapeutic effects of the DC-based vaccines in our settings. Taken together, our data demonstrate that DC-based vaccines represent a rational tool for the treatment of human prostate cancer. Pracoviště Ústav molekulární genetiky Kontakt Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Rok sběru 2018
Počet záznamů: 1